Humabs BioMed Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 37
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Humabs BioMed General Information

Description

Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The company's human monoclonal antibodies have passed natural selection by the human immune system in response to viral and bacterial diseases, in addition it also developes anti-infective immunotherapies for the traetment of induce protective and therapeutic immune responses which solutions are non-existent or inadequate, enabling patients and pharmaceutical companies to get drugs for the treatment of rare diseases.

Contact Information

Website
www.humabs.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Drug Discovery
Parent Company
Primary Office
  • Via Mirasole 1
  • 6500 Bellinzona
  • Switzerland
+41 091 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Humabs BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Humabs BioMed‘s full profile, request access.

Request a free trial

Humabs BioMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The comp
Other Pharmaceuticals and Biotechnology
Bellinzona, Switzerland
37 As of 2021
000000&0

00000000

re magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000 000000000
Seattle, WA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000 000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Humabs BioMed Competitors (67)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OncoResponse Venture Capital-Backed Seattle, WA 00 00000 00000000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Schlieren, Switzerland 0 000.00 00000000000 000.00
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 00 00000 00000000000 00000
000000000000000 Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
You’re viewing 5 of 67 competitors. Get the full list »

Humabs BioMed Patents

Humabs BioMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3898668-A2 Antibodies that neutralize hepatitis b virus and uses thereof Pending 19-Dec-2018 0000000000
AU-2019403245-A1 Antibodies that neutralize hepatitis b virus and uses thereof Pending 19-Dec-2018 0000000000
CA-3121004-A1 Antibodies that neutralize hepatitis b virus and uses thereof Pending 19-Dec-2018 0000000000
US-20210284718-A1 Antibodies against campylobacter species Pending 17-Jul-2018 00000000000
AU-2019306543-A1 Antibodies against campylobacter species Pending 17-Jul-2018 C07K16/121
To view Humabs BioMed’s complete patent history, request access »

Humabs BioMed Executive Team (3)

Name Title Board Seat Contact Info
Davide Corti Ph.D Senior Vice President and Chief Scientific Officer
Nadia Passini Ph.D Director of Research and Development Operations and Translational Science
Filippo Riva Managing Director, Chief Financial Officer and Chief Executive Officer
To view Humabs BioMed’s complete executive team members history, request access »

Humabs BioMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial